LTZ Therapeutics Announces FDA Clearance of IND Application for LTZ-232 to Treat Advanced Metastatic Colorectal Cancer and Other Solid Tumors

LTZ Therapeutics announced that the US FDA has cleared its Investigational New Drug (IND) application to evaluate LTZ-232 to treat patients with advanced metastatic colorectal cancer and other solid tumors.